PCRX 250516 17.50C(PCRX250516C17500) Stock Price Today

English
中文繁體
中文简体

Dark
Light

Open Account

Download

Clear

All

Quotes

News

Learn

Help

All

News

Announcements

No matches yet

Operations too frequent. Please try again later.

Please check network settings and try again Refresh Refresh

History record

PCRX250516C17500

Watchlist

4.20
0.000.00%

15min DelayClose May 7 16:00 ET

0.00High0.00Low

Intraday

5D
Daily

News

Preview: Pacira BioSciences's Earnings
BenzingaMay 7 10:03 ET
Pacira BioSciences Announces It Will Present 3-Year Safety And Efficacy Data of PCRX-201 Following Single Intra-Articular Injection For Moderate-to-Severe Knee Osteoarthritis At 2025 European Alliance Of Associations For Rheumatology June 11-14 2025...
BenzingaMay 6 08:03 ET
Earnings Preview: PCRX to Report Financial Results Post-market on May 08
Moomoo NewsMay 2 21:00 ET
Pacira to Report First Quarter 2025 Financial Results on Thursday May 8, 2025
GlobeNewswireApr 29 08:00 ET
Pacira BioSciences Announces 2-Yr Data On PCRX-201 Gene Therapy Demonstrating Sustained Knee Pain Relief
BenzingaApr 28 08:05 ET
Express News | Pacira BioSciences To Present 104-Week Data Of PCRX-201 For Patients With Mild To Severe Osteoarthritis Of Knee
BenzingaApr 22 16:02 ET

Comments

Teddy123

Apr 23 12:27

Pacira BioSciences to Present 104-Week Efficacy Data Following a Single Local Administration of PCRX-201 for Patients with Mild to Severe Osteoarthritis of the Knee

$Pacira BioSciences (PCRX.US)$
Revolutionary Gene Therapy Shows 2-Year Effectiveness for Knee Arthritis After Single Dose

Teddy123

Apr 21 20:17

DOMA Perpetual Supports Pacira's New $300 Million Share Repurchase Authorization as a Meaningful Step to Enhance Value for Shareholders

$Pacira BioSciences (PCRX.US)$
Pacira's Largest-Ever $300M Buyback Signals Major Growth Phase - Key Investor Catalyst Revealed

Teddy123

Apr 3 20:31

Pacira BioSciences Announces First Patient Dosed in Phase 2 Study Evaluating Safety and Efficacy of PCRX-201 for the Treatment of Osteoarthritis of the Knee

$Pacira BioSciences (PCRX.US)$
Game-Changing Knee Osteoarthritis Gene Therapy Advances After 2-Year Pain Relief Success

Value investorr

Aug 24, 2024 00:25

My last point: looking into the future of PCRX.

$Pacira BioSciences (PCRX.US)$ $iShares Russell 2000 ETF (IWM.US)$
Besides all the information that is publicly available and that I’ve posted in my previous two comments. Here’s something to keep in mind for PCRX future if you want to make your decision to buy, hold, or sell:
1. Diversification of product pipeline greatly reduces the risk of further top-line (revenue) erosion even if we assume the worst case scenario for Experal (which itself is ex...

Value investorr

Aug 19, 2024 23:03

A undervalued keeper

$Pacira BioSciences (PCRX.US)$ I believe whoever saw my last comment om this stock has generated a good return over the past week. I think the opportunity is still not fully capitalized and fundamental reasonings from last time still persist.
Additionally, just look at the imsider activities. Wow, from CEO to multiple directors, they are buying and loading a ton of shares and no one is selling. This is just another signal supports my theory and the share price. From its funda...

Share Your Profit/Loss